Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
A proof-of-concept phase 2a trial of oral Minzasolmin (UCB0599) (NCT04658186), an oral alpha-synuclein misfolding inhibitor [110], did not meet primary or secondary clinical endpoints according to a recent press release by its pharmaceutical company
Medical interventions, such as ovulation-inducing medications, may be necessary in some cases
White 2003)
HPLC purity measures the percentage of the UV-absorbing peak area attributable to the target compound under specific chromatographic conditions
US$ 23.45
US$ 29.84
US$ 27.54
US$ 27.02
